Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
Structure and Activity of the Acid Sensing Ion Channels.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
Product Insert, Amiloride HCl Tablets
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
MYRAC Rx
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Plasma exchange in severe attacks of neuromyelitis optica.

Pages